• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • TheStreet Smarts
  1. Home
  2. / Investing
  3. / Stocks

Farm Bill Passes, and These Hemp Companies Will Be Big Winners

Here are 5 hemp companies and 5 hemp states that will benefit the most.
By DEBRA BORCHARDT
Dec 12, 2018 | 10:19 AM EST
Stocks quotes in this article: CWBHF, CVSI, MJNA, ELLXF

The 2018 Farm Bill was passed by the Senate on Tuesday by a vote of 87-13. The next move is that the legislation heads to the House for a vote -- and then if it passes there, it goes to President Trump to be signed into law. It is expected to face no significant challenges.

The impact of this legislation on the cannabis industry is enormous. Last year, hemp sales in the U.S. reached $820 million, according to the Hemp Business Journal. That's without hemp being completely legal. These sales have been projected to reach $2.1 billion by 2020 -- and that's not taking into account the passage of the Farm Bill.

The Hemp Farming Act includes language that will amend the federal list of controlled substances with regards to hemp. It also removes any federal regulations that keep farmers from growing and selling hemp and allows the farmers to collect crop insurance.

The first group to benefit from this is, of course, the farmers and the states where hemp is identified as a crop with a lot of potential. Next are the companies that stand to benefit from focusing their product lines on hemp-derived CBD.

Top 5 Hemp Companies

Cannabis research firm Brightfield Group found that hemp-derived CBD (cannabidiol) sales in the U.S. hit $291 million in 2017. Brightfield also said that with the anticipated passing of the 2018 U.S. Farm Bill, the hemp-derived CBD market is expected to quickly go mainstream and become a $5.7 billion market by next year, and a $22 billion market by 2022 -- nearly 40x its current size. This number tends to be larger than most other hemp market estimates.

Brightfield's senior analyst, Jamie Schau, said: "We believe that blowing market sizes and growth figures out of proportion would do our customers and the market a great disservice. This year's hemp CBD forecasts might seem like a departure from that view, but I assure you they are not. These numbers reflect the substantial changes we anticipate will follow full federal legalization of hemp-derived CBD, a prospect that is no longer a pipe dream but looking more and more likely as bipartisan support for hemp and its extracts continues to grow."

Brightfield Group provided a chart of the top twenty hemp-derived CBD companies -- and four the top five are publicly traded. CW Hemp or Charlotte's Web Holdings (CWEB.CN) (CWBHF) , CV Sciences (CVSI) , Medical Marijuana (MJNA) and Elixinol (ELLXF) .

Market by 2022 -- nearly 40x its current size.

Figure 1 provided by Brightfield Group

Charlotte's Web has really bounced back after having received a warning letter from the FDA. In 2017, founders the Stanley Brothers were called out by the FDA for making claims that couldn't be substantiated.

"Your products, "Everyday Dietary Supplement," "Everyday Plus Dietary Supplement," "Everyday Advanced Dietary Supplement" and "Charlotte's Web Gel Pen," are not generally recognized as safe and effective for the above-referenced uses and, therefore, the products are "new drugs" under section 201(p) of the Act [21 U.S.C. § 321(p)]. New drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from the FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. §§ 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective."

Since then, the company rephrased its website and many other CBD companies dialed down the promises of efficacy. The stock, listed in Canada, has moved from C$8.13 to a year high of C$20.76 and was lately trading at C$16. Charlotte's Web recently reported financial results for its third quarter, with revenue growth of 57%, to $17.7 million, versus last year's $11.3 million for the same time period. Gross profits increased 54%, to $13.8 million over last year's $9 million for the same time period.

CV Sciences had over a 200% increase in sales across the board year over year. The company is number two in the market, with an 11% of overall market share. Its 2017 sales were $34.7 million and 2018 expected sales are $74.3 million. The company just built expansive manufacturing operations, which also house numerous marketing and distribution teams responsible for a growing list of consumer products and marijuana edibles containing plant-based CBD. CV Sciences is helping to secure San Diego as a global hub for the state's cannabis supply chain after the passing of favorable local and federal regulations.

Medical Marijuana has 10% of the overall market. Its 2017 sales were $32.2 million, and in 2018 it's expected to report sales of $79.0 million. The company's main product is Kannaway and through its direct sales model, it has been the company's largest stream of revenue. The model continues to see success in a market where formal advertising and marketing are limited.

Elixinol is number five in the market and has a 4% share of the overall market. Its 2017 sales were $13.4 million and 2018 expected sales are $25.4 million. Brightfield noted that Elixinol has strategic partnerships with medical professionals, leveraging relationships to expand CBD education and brand name recognition.

Brightfield said, "The Act will be a boon to the legal hemp CBD industry, and a great relief to farmers and producers who have been sidelined by vague federal laws forcing them to compete on an unfair playing field against gray and black-market actors, and even international importers."

Top 5 Hemp States

The top five states whose hemp industry will benefit from the farm bill, according to the Hemp Industry Daily, are Colorado, Kentucky, Oregon, North Carolina and Vermont. Colorado already produces 50% of the country's hemp. Kentucky has more acres licensed, but Colorado has more in production. Oregon's hemp requires some of the same testings as consumable cannabis. This means it doesn't have the same exposure to pollutants that Chinese hemp has and makes it a desirable product for producers.

Hemp Industry Daily said that North Carolina has more growers, more acres and more processors than any other state in its first year of hemp production. The state has really focused a lot of effort on the crop. Vermont has 90 licensed growers and 560 licensed outdoor acres for growing hemp. This little state has flexed its hemp muscle.

"The Farming Act provides much-needed certainty, so hemp farmers and hemp businesses can provide the goods people want," said Gabriel Ettenson, President of Elixinol. "Hemp is a positive contributor to the U.S. economy and culture. Hemp is a clean agricultural product and has great potential to enhance our collective wellness and global environment." Elixinol currently buys its hemp raw products from Colorado, but the company sees this language as a positive step for U.S. hemp businesses and the U.S. economy.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Borchardt had no positions in any of the securities mentioned.

TAGS: Fundamental Analysis | Investing | Markets | Politics | Stocks | Analyst Actions | Cannabis

More from Stocks

Rule of the Week: Don't Fight the Fed

James "Rev Shark" DePorre
Jan 30, 2023 4:33 PM EST

We've got a mix of earnings, a rate decision and nervous investors.

3 High-Yield Dividend Tech Stocks for Income Investors

Bob Ciura
Jan 30, 2023 2:35 PM EST

Now could be a very good time to capitalize on sustainable income streams from a sector where dividend income is scarce.

Checking on AMD's Stock Charts Ahead of Tuesday's Earnings

Bruce Kamich
Jan 30, 2023 2:10 PM EST

Here's what to avoid for now.

Is This Mid-Cap Oil Stock Ready to Capture Its 'Big Winner' Potential?

Bruce Kamich
Jan 30, 2023 1:29 PM EST

Here's our technical strategy for trading oil producer Denbury.

Don't Fight the Fed? What About When the Fed Is Fighting Its Own Past?

Peter Tchir
Jan 30, 2023 1:00 PM EST

The biggest risk to markets in the coming weeks is the realization that the Fed has already gone far too far, and the economy is rolling over.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 12:27 PM EST REAL MONEY

    LIVE EVENT: Chris Versace and "Sarge" Guilfoyle Share Their Stock Market Insights

    This Monday, Jan. 30, at 12 p.m., our very own exp...
  • 11:48 AM EST REAL MONEY

    Watch Doug Kass on the Daily Rundown!

    In today's Action Alerts PLUS Daily Rundown, Doug ...
  • 11:03 AM EST JAMES "REV SHARK" DEPORRE

    This Weekend On Real Money

    It's time to start using this power to build great...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2023 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login